Botulinum toxin type A
This document is technical information about materials. It does not recommend any procedure or product.
In brief
A purified neurotoxin protein that blocks acetylcholine release at the neuromuscular junction, reducing the muscle contraction that creates dynamic lines. It is the one entry in this reference that does not act on the extracellular matrix at all, and the only one classified as a prescription medicine rather than a device.
Regulatory identity by market
COS cosmetic · MD medical device · RX drug · — not established in public sources
Identity & physical properties
| Synonyms | Botulinum toxin type A, Botulinum neurotoxin A, BoNT-A, Neuromodulator |
|---|---|
| Family | Neuromodulator — bacterial neurotoxin protein |
| Morphology | Lyophilised powder reconstituted before injection |
| Molecular weight | Supplied as a protein complex; potency is expressed in units defined by each manufacturer's own assay and units are not interchangeable between preparations |
Mechanism
The reported mechanism is at the neuromuscular junction, not in the dermis. The toxin cleaves proteins required for acetylcholine vesicle release, so the signal from nerve to muscle is interrupted and contraction is reduced. No extracellular matrix is supplied and no foreign-body response is provoked, which places this material outside the supply-or-provoke division that organises the rest of this reference.
Evidence
| PMID | Study type | Summary |
|---|---|---|
| 39722351 | review | Systematic review of currently used injection techniques for aesthetic use in facial and cervical regions |
| 35178552 | review | Systematic review and network meta-analysis of complications from cosmetic upper-face injections |
| 35965899 | review | Review of the intradermal microdroplet technique and how it differs from conventional intramuscular placement |
| 34378298 | review | Review of blepharoptosis from local toxin spread, covering anatomy, prevention and management |
Regulatory identity — detail
| Market | Classification | Note | Basis |
|---|---|---|---|
| KR | drug | Regulated as a medicine under the Pharmaceutical Affairs Act, not under the medical device framework that covers the other materials in this reference. Advertising rules for prescription medicines are correspondingly stricter. | Legal text |
| EU | unclassified | Not established from public sources as of the revision date below, though the medicinal-product pathway is the expected route given the classification in the two markets confirmed here. | — |
| US | drug | Licensed as a prescription biologic under BLA 103000, with marketing status recorded as prescription. This is the drug pathway, not the device pathway used by the fillers and biostimulators in this reference. | Legal text |
| JP | unclassified | Not established from public sources as of the revision date below. | — |
| CN | unclassified | Not established from public sources as of the revision date below. | — |
| VN | unclassified | Not established from public sources as of the revision date below. | — |
Limitations & open questions
Potency units are defined by each manufacturer's own assay and are not interchangeable, so a dose stated for one preparation does not convert to another. The evidence cited here is review-level and technique-focused; this page does not carry efficacy figures because dose, placement and interval vary by protocol and by the muscle treated. Adverse events from local spread, including eyelid ptosis, are documented in the literature cited above and are reported to occur more frequently with less experienced injectors.
All statements on this page are drawn from the cited literature. Where a market’s regulatory classification could not be established from public sources, it is marked as not established rather than inferred.
This one sits outside the atlas axis
Every other entry here either supplies extracellular matrix or provokes the host to build it. This material does neither. It reduces the muscle activity that folds the skin, so the line softens without anything happening in the dermis. Grouping it with fillers and biostimulators because all three are injected obscures that the mechanisms have nothing in common.
The regulatory lane is different in kind
The fillers and biostimulators in this reference travel the medical device route. This is a medicine. That changes who may supply it, how it may be discussed, and what may be said about it in public — which is why this page describes the substance and its pathway and stops there.
Units do not transfer
Potency is measured by assays that each manufacturer defines. A number expressed in units is meaningful only alongside the preparation it was measured for. This is the single most common place where information is carried incorrectly from one product to another.